+49 30 46307-200


Pylopass™ is a proprietary strain of Lactobacillus reuteri which specifically coaggregates with Helicobacter pylori in the stomach to reduce the bacterial load. Pylopass™ is comprised of spray-dried L. reuteri cells and is stable in a wide range of applications for the end consumer market.


The Pylopass™ strain of L. reuteri was identified after a detailed, multi-year screening process. It was selected as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lactobacillus species of the ORGANOBALANCE culture collection of food grade strains. Through a specific mechanism, Pylopass™ forms coaggregates with H. pylorito decrease the overall load in the stomach, thereby decreasing the risk of developing gastritis and peptic ulcer disease.

The surface structures on Pylopass™ contain adhesion molecules that recognize and adhere to surface structures on H. pylori.

After coaggregation in the stomach has occurred, the entire coaggregate is excreted from the body through the digestive tract. Pylopass™ specifically binds to H. pylori and does not alter the microflora of the gut.


Advantages over probiotics

Product stability:
Unlike probiotics, Pylopass™ consists of inactivated cells which can withstand environmental fluctuations. For shipment and storage, Pylopass™ does not require temperature controls.

Specificity for H. pylori:
While probiotics cater to general gut health, Pylopass™ specifically binds H. pylori in the stomach. Furthermore, Pylopass™ does not bind or disturb the normal gut microbial balance.

Stability in gastric conditions:
In contrast to probiotics, Pylopass™ employs a mechanism which is not dependent on survival in the gastric environment. Probiotics can be beneficial because they may replace harmful bacteria in the gastrointestinal tract. However it is uncertain whether such living probiotic strains can withstand the acidic environment in the stomach. This concern is not a challenge for Pylopass™ as the coaggregation depends only on the binding of surface structures between Pylopass™ and H. pylori.

Advantages over antibiotics

Good tolerability:
Triple and even quadruple antibiotic therapies are non-specific and have numerous side effects such as diarrhea and taste disturbances. On the contrary, there are no side effects related to Pylopass™ ingestion or administration.

No risk of antibiotic resistance:
Research shows that the number of antibiotic resistant strains of H. pyloriis increasing globally. In Asia, an estimated 37% of cases are resistant to metronidazole and 65% of cases are resistant to amoxicillin in Africa4. Ramakrishna has argued against the case of eradication, as treatment with antibiotics may prove ineffective, due to high frequencies of antibiotic resistant strains5. Pylopass™ offers an alternative management modality that does not contribute to the problem of antibiotic resistance.


The UBT Test

Human clinical trials have been able to show the effect of Pylopass™ supplementation on Helicobacter pylori load. The study by Mehling and Busjahn used a crossover study design with a two-week placebo period followed by a two-week supplementation period with Pylopass™6.

Study participants took Pylopass™ with their morning and evening meals with a daily dose of 200 mg/day. The effect of Pylopass™ was measured via 13C urea breath test (UBT). The UBT is a rapid non-invasive diagnostic method of testing for H. pylori infection based upon the ability of H. pylori to convert urea to ammonia and carbon dioxide by urease activity. The statistically significant effect of Pylopass™ after the two-week supplementation period is depicted.

In another single-blinded and placebo control led study Holz et al.7 determined the impact of two-week oral intake of Pylopass™ on H. pylori load, applying a daily dose of 2 x 1010 non-viable lyophilized Lactobacillus reutericells (equivalent to 200 mg Pylopass™). This intervention led to a significant decrease in H. pyloriload in healthy subjects with detectable H. pylori infection in a general population sample.

The reduction of H. pylori was detected by UBT. Treatment by placebo did not result in a significant change in 13 C UBT (∆ placebo -0.6 ± 5.3), whereas verum treatment significantly reduced 13 C UBT values (∆ verum -4.9 ± 7.8, p = 0.026 vs. placebo).


1 Go MF (2002) Review article: Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 16: 3–15

2 Fock KM & Ang TL (2009) Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroen Hepatol 25: 479– 486

3 Malfertheiner P et al. (2012) Management of Helicobacter pylori infection – the Maastricht IV/ Florence consensus report. Gut 61: 646–664

4 De Francesco V et al. (2010) Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 19: 409– 414

5 Ramakrishna BS (2006) Helicobacter pylori infection in India: the case against eradication. Indian J Gastroenterology 25: 25–28

6 Mehling H & Busjahn A. (2013) Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control. Nutrients 5: 3062–3073

7 Holz C et al. (2014) Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A pilot study. Probiotics & Antimicro. Prot. 7: 91–100


Quality and Safety at a glance:
    - Qualified Presumption of Safety (QPS) status in the EU
    - GRAS status in the US
    - No antibiotic resistance
    - Manufactured according to HACCP guidelines
    - Halal certified
    - Vegetarian, non-GMO and solvent free


Microbial fermentation is a one of ORGANOBALANCE’s core competencies. Pylopass™ is produced via fermentation in a controlled production facility.

Because the coaggregation activity is of utmost importance, Pylopass™ is produced by standardization to coaggregation levels. This differs from a traditional probiotic, which is fermented to obtain a certain cell count.

This means that Pylopass™ products have been fermented to their peak aggregation abilities. After fermentation, the cells are harvested, suspended in a matrix and spray dried to obtain a free flowing powder.


As a raw ingredient manufacturer, we not only actively promote our ingredients on a business-to-business level, but we also support our customers in many ways.

Regulatory Support
Our regulatory experts collaborate with authorities and organizations globally to work towards a regulatory situation that is in favor of Pylopass™ products. We have years of experience with regulatory dossiers and a track record of successful regulatory initiatives.

Formulation Support
Due to the stable nature of Pylopass™, it does not need to be refrigerated and can be used as a dietary supplement, in powdered beverages and in fermented dairy products. Based on human studies, the recommended daily dose of Pylopass™ is 200 mg, which can be divided into several servings per day. One gram of Pylopass™ contains approximately 100 billion Lactobacillus reuteri cells.

Scientific Support
ORGANOBALANCE collaborates with universities and research centers around the world to strengthen the scientific backing of Pylopass™. We maintain a database of published literature which is used by our technical experts to provide tailor-made, well researched answers on technical questions.


Your details:

* Required



  • Gustav-Meyer-Allee 25
  • 13355 Berlin
  • Germany
  • info@organobalance.com
  • Tel.: +49 30 46307-200
  • Fax: +49 30 46307-210
  • www.organobalance.de
  • www.pylopass.com
  • ORGANOBALANCE on Youtube